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Abstract 
A complex network of interacting pathways involving renal, neural, endocrine, 
vascular and other mechanisms controls the main determinants of blood pressure - 
cardiac output and total peripheral resistance. Multiple genes within each of these 
systems contribute to the specialized functions regulating blood pressure. The 
monogenic forms of blood pressure dysregulation have provided valuable insights 
into blood pressure regulation and expanded our understanding of both the 
mechanisms and the treatment of hypertension. Genome wide association studies 
have identified over 100 single nucleotide polymorphisms associated with blood 
pressure phenotypes and have identified plausible novel pathways of BP regulation 
and putative drug targets.  
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From an epidemiological and clinical perspective, blood pressure (BP) at the higher 
end of the normal population distribution is associated with an increased risk of 
cardiovascular mortality and morbidity. Traditionally cardiovascular risk assessment 
is based on a predefined threshold at which the quantitative BP phenotype is 
converted into a binary trait (hypertension). Modern management strategies are 
directed towards BP reduction below this threshold at which the risk of excess 
cardiovascular events is reduced. Thus, the BP or hypertension (HTN) phenotype is 
a measurable characteristic of clinical risk, and discovering their genetic 
determinants will allow early risk prediction and targeted treatment. A complex 
network of interacting pathways involving renal, neural, endocrine, vascular, and 
other mechanisms controls the main determinants of BP - cardiac output and total 
peripheral resistance. Multiple genes within each of these systems contribute to the 
specialized functions regulating BP, and hence it is likely that many genes will 
participate in the development of HTN. Thus, by definition, BP is a complex trait that 
refers to any phenotype that does not exhibit classic Mendelian inheritance attributed 
to a single gene and results from the interactions between multiple genes and 
environmental factors. The distribution of BP in the population is a normal unimodal 
distribution supporting a complex multifactorial basis of BP regulation (1, 2). 
However, there are monogenic forms of HTN or hypotension (“Simple trait”) which 
are very rare in the population and have little to no impact on public health, in 
contrast to essential HTN with a prevalence of ~27% amongst the adults worldwide. 
The monogenic forms of BP dysregulation have provided valuable insights into BP 
regulation and expanded our understanding of both the mechanisms and the 
treatment of HTN. The monogenic forms have also been the most successful 
examples of gene mapping with mutations in over 25 genes now linked to perturbed 
gene function and the BP dysregulation. The goal is to extend these successful 
examples to essential HTN. 
Evidence for a genetic basis of essential hypertension 
 
Whilst monogenic syndromes of HTN provide evidence that disruption of gene 
function can have a major impact on BP, to venture into formal genetic dissection of 
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BP or essential HTN requires evidence for a genetic contribution to these traits. 
Strong indication that BP and essential HTN may have a genetic component came 
from family studies demonstrating correlation of BP among siblings and between 
parents and children with part of this correlation attributable to genetic factors. Sir 
George Pickering noted a correlation coefficient of about 0.2 among BP of 
hypertensive propositi(3) and the relationship was similar to those of height. The 
Montreal adoption study(4) demonstrated correlation coefficients of 0.38 and 0.16 
between biological and adoptive sibs, respectively, while the Victorian Family Heart 
Study(5) estimated correlation coefficients of 0.44 for non-twin siblings, 0.78 for 
monozygous twins, 0.50 for dizygous twins and 0.12 for spouse-spouse pairs. All 
these data indicate presence of a genetic component if the environmental influence 
is assumed to be similar between comparison groups. Hunt et al.(6) studied life table 
data for 94,292 persons and found the relative risks of developing HTN were 4.1 in 
men and 5 in women aged 20-39 who had at least two first degree relatives affected 
by HTN. Two additional measures that are commonly used to assess the genetic 
component of a trait are heritability (h2), which is the fraction of variation in disease 
susceptibility due to genetic factors, and sibling recurrent risk (s) which is the 
degree of elevated risk of disease for a sibling of an affected individual compared 
with a member of the general population. The heritability of clinic systolic BP is 
around 15-40% and 15-30% for clinic diastolic BP,(7, 8) whereas for ambulatory 
night-time systolic and diastolic BP the heritabilities are 32-70% and 32-50%.(7-11). 
It is pertinent to point out that though the heritability estimates are considerable, this 
does not equate to magnitude of genetic effect. This is because the denominator in 
the estimate of heritability comprises measurement error and variances attributable 
to genes, shared environment, non-shared environment and unmeasured 
determinants. Heritability is also a property of the population studied and low 
heritability estimates would suggest that genetic mapping would be difficult for that 
phenotype. The sibling recurrent risk of HTN is around 1.2-1.5(12) and taking this 
along with heritability and correlation estimates, the HTN and BP can be considered 
a trait with relatively modest genetic effect. As noted above, minimizing 
measurement error by using ambulatory recordings provide higher heritability 
estimates and using this phenotype can maximize the genetic signal (9-11).  
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Genetic architecture of blood pressure and hypertension 
 
To successfully map the genetic basis of a trait, a good understanding of the genetic 
architecture of the trait is required. The genetic architecture of a trait refers to the 
number of disease variants that exist, their allele frequencies, the risks that they 
confer, and the interactions between multiple genetic and environmental factors. 
Mutations that account for Mendelian forms of HTN are highly penetrant and are 
usually under very strong selection, which keeps them at low frequencies with high 
levels of allelic heterogeneity. In contrast, susceptibility variants involved in essential 
HTN are likely to have low or medium penetrance and are probably not subject to 
such strong selection resulting in lower allelic heterogeneity. There is an ongoing 
debate whether common or rare variants contribute to essential HTN. Single 
nucleotide polymorphisms (SNPs) with minor allele frequency (MAF)>1% account for 
more than 90% of the genetic differences between individuals and thus are likely to 
contribute to the population variation in BP rather than rare variants. This is the basis 
of the common disease/common variant (CDCV) hypothesis which states that  
genetic variants underlying complex traits occur with a relatively high frequency, 
have undergone little or no selection in earlier populations and are likely to date back 
to more than 100 000 years ago (13). Indeed from an evolutionary perspective, 
essential HTN is a disease of civilization and may be an undesirable pleiotropic 
effect of a preserved genotype that could have optimized fitness in the ancient 
environment (14). It is well recognized that HTN occurs earlier and with more 
severity in people of African ancestry compared to those of European ancestry (15). 
Differing predispositions to HTN in different populations may simply reflect different 
evolutionary selection pressures (“bottlenecks”) and the fact that populations do not 
share the same ancestral histories. In addition, an allele with no effect on 
reproductive fitness is expected to achieve high equilibrium frequency and this is 
likely to be the case for genes influencing HTN. The other competing model for HTN 
is the common disease rare variant hypothesis, with an inverse relationship between 
the magnitude of genetic effect and allele frequency. This model argues that 
diseases are common because of highly prevalent environmental influences, not 
because of common disease alleles in the population. Recently support for this has 
come from studies of rare variants of three genes namely Solute Carrier Family 12 
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Members 1 and 3 (SLC12A1, SLC12A3), and Potassium Voltage-Gated Channel 
Subfamily J Member 1 (KCNJ1) (major mutations of which cause Gitelman 
syndrome, and Bartter syndrome type 1 and 2 respectively) in the general population 
producing clinically significant BP reduction and protection from development of HTN 
(16). The most likely scenario would be that the allelic spectrum of the disease 
variants is the same as the general spectrum of all disease variants. Under this 
neutral model, although most susceptibility variants are rare with minor allele 
frequencies (MAF) <1%, SNPs with MAF>1% would account for more than 90% of 
the genetic differences between individuals. It is plausible that these common 
variants might contribute significantly to those common diseases in which 
susceptibility alleles might not be under intense negative selection. For the genome 
as a whole, it has been predicted that of the expected 10-15 million SNPs with 
MAF>1%, approximately half have MAF>10%. Given that the number of disease 
variants conferring mild to moderate risks might be large, there are likely to be 
hundreds of common and rare variants contributing to the familial clustering of HTN. 
Monogenic forms of hypertension and hypotension 
Table 1 summarises the rare monogenic forms of HTN that have contributed to our 
understanding BP regulation and targeted treatment (17, 18). We briefly describe 
each of the syndromes below. 
Glucocorticoid-Remediable Aldosteronism or Familial Hyperaldosteronism Type 
1  
This rare autosomal dominant disorder is caused by the formation of a chimeric gene 
due to unequal crossing during meiosis. This results in aldosterone secretion 
stimulated by ACTH instead of angiotensin II resulting in HTN in childhood and early 
adulthood due to the secretion of ACTH as a fusion product of 5’ end of Cytochrome 
P450 Family 11 Subfamily B Member 1 (CYP11B1) and the distal coding sequence 
of member 2 of the same family (CYP11B2) (19). Affected individuals are treated 
with a low-dose of glucocorticoids to supress ACTH secretion, amiloride to block 
ENaC, or spironolactone to prevent aldosterone binding to the mineralocorticoid 
receptor. 
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Apparent Mineralocorticoid Excess 
Normally cortisol has mineralocorticoid activity which does not manifest as cortisol is 
metabolised promptly into cortisone by 11-Beta-Hydroxysteroid Dehydrogenase 
Type 2 (HSD11B2). In Apparent Mineralocorticoid excess (AME), absence or 
reduced activity of HSD11B2 results in cortisol acting as a potent mineralocorticoid. 
HSD11B2 activity is reduced by loss of function mutations and from excess ingestion 
of licorice whose active constituent is the glycyrrhizic acid. Treatment is with 
spironolactone which blocks the binding of cortisol to mineralocorticoid receptor and 
a low sodium diet (20). 
Pseudohypoaldosteronism type II (Gordon’s syndrome) 
This syndrome is caused by mutations in the WNK Lysine Deficient Protein Kinase 1 
and 4 (WNK1, WNK4), Kelch Like Family Member 3 (KLHL3), and Cullin 3 (CUL3). 
Mutations in the WNK genes cause a disruption in the signalling pathway that 
regulates the BP by controlling the ion cotransporters NCC and NKCC2 in the 
kidney. CUL3 and KLH3 mutations, on the other hand, inhibit the ubiquitylation of 
WNK4 and other WNK isoforms leading to an over-activation of NCC/NKCC2 and 
thereby increased salt retention and HTN (21) (22). Affected individuals or subjects 
are treated with either a low-salt diet or thiazide diuretics which block NCC. 
Liddle syndrome 
This is an autosomal dominant condition with low levels of aldosterone and renin. 
Normally, a regulatory repressor called Nedd4-2 : Neural Precursor Cell Expressed, 
Developmentally Down-Regulated 4-Like, E3 Ubiquitin Protein Ligase (NEDD4L) 
binds to the sodium channel ENaC and promotes its degradation (23). Mutations in 
Sodium Channel Epithelial 1 Beta and Gamma Subunits (SCNN1and SCNN1G), 
coding for the β and γ subunits of ENaC respectively, disrupts this binding leading to 
the constitutive expression and prolongation of the half-life of ENaC resulting in 
increased sodium reabsorption, volume expansion, and HTN. Treatment is with 
amiloride or triamterene. 
Bartter's syndrome 
This syndrome leads to loss of salt with hypokalemic metabolic alkalosis, normal to 
low BP and increased renin and aldosterone levels. It is caused by the direct loss of 
function of NKCC2 or a secondary cause disrupting the functions of NKCC2-ROMK 
channel, Chloride Voltage-Gated Channel Kb (CLCNKB), Bartin and Calcium 
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Sensing Receptor (CaSR) in the TAL cells (24).  Individuals with this syndrome 
exhibit an increased level of urine prostaglandin E2 and reduced susceptibility to 
angiotensin II and norepinephrine. Treatment is with a potassium supplementation, 
and use of cyclooxygenase inhibitors, ACE- inhibitors and potassium sparing 
diuretics.  
Gitelman's syndrome 
Loss of function mutations in the SLC12A3, producing NCC in the DCT cells, lead to 
Gitelman’s syndrome, which has a prevalence of 1:40000. Treatment options include 
oral potassium and magnesium supplementations with adequate salt and water 
consumption, and prescription of indomethacin, amiloride and eplerenone (25). 
Primary Aldosteronism 
This syndrome is characterised by the constitutive production of aldosterone leading 
to HTN with hypokalemia and suppressed circulating renin. Gain of function 
mutations in the gene Potassium Voltage-Gated Channel Subfamily J Member 5 
(KCNJ5) resulting in membrane depolarisation and enhanced aldosterone production 
has been associated with over 40% of these aldosterone-producing adenomas 
(APAs). Other implicated genes include ATPase Na+/K+ Transporting Subunit Alpha 
1 (ATP1A1), encoding the α1 subunit of Na+/K+-ATPase, in 7% of APAs; ATPase 
Plasma Membrane Ca2+ Transporting 3 (ATP2B3), encoding Ca2+-ATPases 
(SERCA); and Calcium Voltage-Gated Channel Subunit Alpha1 D (CACNA1D), 
encoding an L-type Ca2+ channel, CaV1.3 (26); and other gain of function mutations 
in genes regulating Na+, Ca2+, CACNA1D and ATP1A1. 
Phaeochromocytomas and paragangliomas 
These are rare neuroendocrine tumours in the adrenal glands, and sympathetic and 
parasympathetic paraganglia. Phaeochromocytomas, inherited as an autosomal 
dominant trait, are a result of mutations in the Ret Proto-Oncogene (RET), 
responsible for the normal development of neurons. Other implicated genes include 
Von Hippel-Lindau Tumor Suppressor (VHL), Kinesin Family Member 1B 
(KIF1Bbeta), Egl-9 Family Hypoxia Inducible Factor 1 (PHD2), Succinate 
Dehydrogenase Complex Assembly Factor 2 (SDHAF2), and the genes encoding 
the four subunits of succinate dehydrogenase: Succinate Dehydrogenase Complex 
Iron Sulfur Subunit A, B, C, and D (SDHA, SDHB, SDHC and SDHD). Heterozygous 
germline mutations in SDHC and SDHD are associated with paraganglioma type 1, 3 
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and 4 (27). Germline mutation in the SDHB gene is the only reliable predictor of 
malignant Paragangliomas. Type 2 multiple endocrine neoplasia (MEN 2) is a rare 
familial cancer syndrome caused by mutations in the RET gene and is associated 
with phaeochromocytoma. 
Polygenic hypertension 
 
Major advances in identifying common variants associated with BP and HTN arose 
from genome wide association studies (GWAS). GWAS are large scale association 
mapping making no assumptions of the genomic location or function of the causal 
variant and provide a comprehensive approach to testing the hypothesis that 
common alleles contribute to heritable phenotype variation. GWAS rely on the 
linkage disequilibrium (LD) or correlation patterns of SNPs with functional variants 
and, therefore, identified SNPs are usually proxies of untyped functional variants. A 
typical GWAS experiment consists of genotyping 500,000 to 1 million SNPs across 
the genome, as depending on the population this number of SNPs is adequate to 
interrogate 80% of common SNPs with MAF greater than 5%. To adjust for multiple 
testing and to decrease type I error (false-positive rates), the statistical burden of 
proof relies on stringent P-values usually P<5x10-8. Table 2 summarises the GWAS 
results for BP and HTN in different ancestries. One successful GWAS for HTN used 
an extreme case-control design representing the top 2% and bottom 9% of the BP 
distribution. Combined with follow-up validation analyses in 19,845 cases and 16,541 
controls, it confirmed a locus near the Uromodulin (UMOD) gene (28). UMOD is 
exclusively expressed in the kidney, suggesting that the discovered variant may 
influence sodium homeostasis.  Additionally, rare nonsynonymous variants in salt-
handling genes have been shown to have comparatively large effects on BP in the 
general population(16). It is striking that the signals from all the GWAS for HTN and 
BP do not contain genes from highly plausible pathways, for example, the renin-
angiotensin-aldosterone pathway or epithelial sodium channels. An important 
limitation of GWASs is that genome-wide significant SNPs often merely tag but do 
not provide direct information on the causal variants. To translate those signals into 
biological function, follow-up studies are necessary. Another issue arising from 
GWAS studies is the small fraction of population variance of BP (<5%) and BP 
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heritability (~2%) that are explained by the collective effect of all the GWAS loci 
identified so far.(29, 30). The missing heritability (30) conundrum is not unique to BP 
genetics, but is observed in most of the common phenotypes. 
 
Despite the increasing pace of discovery of variants associated with BP and HTN, 
the limited predictive utility of these variants either singly or as part of a composite 
risk score is striking (29). The population distribution of the number of BP increasing 
alleles with nearly similar allele frequencies is normally distributed, as each SNP is 
inherited independently and hence the number of individuals in the population 
expected to carry all harmful risk alleles would be vanishingly small. One way of 
maximising information about the genetic signals is to create a composite genetic 
risk score coding for the presence or absence of risk alleles and their numbers for all 
the BP GWAS SNPs (29). In the ICBPGWAS (31), between the top and the bottom 
quintiles of the risk score a 4.6 mmHg systolic and 3.0 mmHg diastolic BP difference 
was detected, and the prevalence of HT was 29% compared to 16% in the top and 
bottom deciles. The score was also associated with early and advanced target organ 
damage including left ventricular hypertrophy, stroke and coronary artery disease but 
not chronic kidney disease or markers of renal function (32). The lack of association 
between BP risk score and kidney function may reflect just an association with GFR 
but not with other renal phenotypes such as albuminuria, or may indicate that high 
BP and renal disease do not necessarily have the same molecular origin. Using 
panels of genetic markers to predict risk has very poor discrimination and that the 
utility of GWAS approaches are primarily in identification of novel pathways. Below 
we describe some examples of plausible pathways identified by GWAS studies. 
Functional characterisation of GWAS loci - Novel pathways 
 
Uromodulin 
Uromodulin is a protein expressed exclusively in the thick ascending limb of the loop 
of Henle (TAL) and encoded by the gene UMOD. Although the specific function is 
unknown, knockout mice demonstrate an increased localisation of NKCC2 in the 
subapical vesicles of TAL cells with reduced phosphorylation (33). This results in 
reduced co-transporter activity and greater sodium excretion. Alternatively, 
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overexpression of Umod causes a dose dependent increase in the excretion of the 
protein, associated with an elevation of BP. A GWAS of BP extremes linked an 
UMOD SNP rs13333226 to HTN, with the minor G allele conferring a lower risk of 
HTN and reduced urinary UMOD excretion (28). Furosemide, a loop diuretic and 
specific blocker of NKCC2, has been shown to enhance natriuresis and reduced BP 
in both transgenic mice and hypertensive individuals homozygous for the A allele of 
this SNP (34).  
Natriuretic peptide 
Polymorphisms in the ANP and BNP propeptides encoding genes, Natriuretic 
Peptide A and B (NPPA, NPPB), have been associated with natriuretic peptides and 
BP (35, 36). Healthy individuals who are homozygous for the risk allele of SNP 
rs5068, present in the 3’-UTR of NPPA, were found to have lower expression of ANP 
propeptide, NT-proANP, possibly mediated by miR-425. This effect on circulating 
NT-pro-ANP is comparable to the environmental change induced by switching from 
an extremely low salt diet of 230mg/dl to 4600mg/dl (37). Natriuretic Peptide 
Receptor 3 (NPR3) is another plausible candidate identified by GWAS. This gene 
encodes for the natriuretic peptide receptor C/guanylate cyclase C (32, 38); KO 
studies have found the mutant mice to have lower BP due to the reduced clearance 
of the natriuretic peptides (39) . In a GWAS conducted for HTN, SNPs nearby this 
gene- rs1173771 has been associated with BP in Europeans (32) while rs1173766 in 
east Asians (38) . 
 
SH2B Adaptor Protein 3 (SH2B3) 
SH2B adaptor protein 3 is an intracellular adaptor protein expressed in the 
hematopoietic and endothelial cells. GWAS studies have found it to be a candidate 
gene for HTN and renal disease (40-43). Studies using mutant Dahl SS/MCW rats 
with a 6-bp deletion wherein the native proline-leucine-glutamate is replaced with a 
single glutamine, Sh2b3em1Mcwi, resulted in the modification of the phosphotyrosine 
peptide binding pocket of the SH2 domain. This significantly reduced the BP of the 
mutant rat, along with reduced renal damage and blunted infiltration of the immune 
cells to the kidneys. Again, transplantation of the bone marrow from Sh2b3em1Mcwi 
mutants to Dahl SS/MCW rats fed at a 2% NaCl salt rich diet led to a significant 
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decrease in the MAP and kidney injury (44). Further studies in KO Sh2b3 mice also 
have implicated the role of this gene in the development of HTN (45).      
Cytochrome P450 Family 17 Subfamily A Member 1 (CYP17A1) 
This gene encodes for cytochrome P450 which mediates the activity of 17a-
hydroxylase in the biosynthesis of mineralocorticoids and glucocorticoids. It also 
mediates 17,20-lyase activity in the sex-steroid biosynthesis (35). Missense 
mutations in this gene is implicated in congenital adrenal hyperplasia with apparent 
mineralocorticoid excess, salt retention and HTN caused by the deficiency of 17a-
hydroxylase. GWAS on HTN have found this gene to be associated with systolic BP 
(43). 
Guanylate Cyclase 1 Soluble Subunit Alpha and Beta (GUCY1A3, GUCY1B3) 
These genes encode the alpha and beta subunits of soluble guanylate cyclase (GC) 
which form a heterodimer to propagate NO signalling (46) (47). Activation of GCs 
also leads to the production of 3’,5’ cyclic GMP that blocks calcium influx and 
dephosphorylates myosin light chains, resulting in smooth muscle relaxation (48, 
49). KO studies in mice have proved to cause HTN (50). GWAS on European 
ancestry have identified SNP rs13139571 on GUCY1A3-1B3 to be associated with 
BP regulation (32). 
Glutamyl Aminopeptidase (ENPEP) 
This gene encodes for a glutamyl aminopeptidase converts angiotensin II to 
angiotensin III, which then activates the AT2 receptor promoting vasodilation. A 
nonsense variant, rs33966350, in a highly-conserved region of this gene, is 
predicted to result in a truncated protein with either a reduced enzymatic activity or a 
target to nonsense-mediated decay. This truncated protein is predicted to lead to a 
predominant angiotensin II signalling, which activates the AT1 receptor causing 
vasoconstriction, and ultimately result in elevated BP (51). This could be used as a 
plausible alternative therapeutic target to ACE inhibitors (32). ENPEP KO mice have 
been found to develop HTN (52). GWAS has identified SNP rs6825911 to be 
associated with BP in east Asians (38). 
Other genes that are plausible candidates from GWAS include Pleckstrin Homology 
Domain Containing A7 (PLEKHA7) (43, 53-56); ATPase Plasma Membrane Ca2+ 
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Transporting 1 (ATP2B1) (32) (57) which encodes for a plasma membrane 
calcium/calmodulin-dependent ATPase, which pumps calcium from the cytosol into 
the ECM; Solute Carrier Family 4 Member 7 (SLC4A7) which encodes for an electro-
neutral sodium bicarbonate co-transporter (32); NADPH Oxidase 4 (NOX4) encodes 
for NADPH oxidase 4, which enhances vasodilation (58); Phosphodiesterase 5A 
(PDE5A) encodes for phosphodiesterase which is responsible for the hydrolysis of 
cGMP and is a target of hypertensive drug sildenafil (58). Solute Carrier Family 14 
Member 2 (SLC14A2), a target of the calcium channel blocker drug nifedipine (58); 
Solute Carrier Family 8 Member A1 (SLC8A1) encodes for a Na+-Ca2+ exchanger 
that alters cardiac contractility and hypertrophy and is expressed in the 
cardiomyocytes (58); Aldehyde Dehydrogenase 2 Family  (ALDH2, mitochondrial) 
encodes for the mitochondrial enzyme alcohol dehydrogenase 2 for alcohol 
metabolism and has been associated with HTN through the modification of alcohol 
consumption (38). 
Future Directions 
Whilst high throughput genomic methods have resulted in the identification of robust 
signals for blood pressure, the translation into clinical applications have been limited. 
In this context, it is worthwhile recognising that GWAS studies are population-based 
studies focussing on associations at a population level. Other points to note are  
GWAS studies SNPs and phenotypes in isolation and has so far ignored pleiotropy, 
environmental interactions and gene-gene interactions. All these are crucial in the 
complex biology of blood pressure and the era of GWAS has laid the foundation of 
robust association study methods which now needs to progress towards studies of 
pathways and networks and biological function that would allow population level 
discoveries to be relevant on an individual level. Alongside this, efforts are ongoing 
on integrating other omics methods such as epigenomics and metabolomics. 
Epigenomics and Hypertension 
Epigenetics refers to heritable changes in gene expression that does not involve 
changes to the underlying DNA sequence. Epigenetic mechanisms involve 
modification of DNA through methylation, histone modification or effect of non-
coding RNA. Unlike genomic variants, epigenetic alterations can be difficult to 
study as they are often tissue or cell-type specific. A genome wide methylation 
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study of leukocyte DNA in a small cohort of 8 African-American hypertensive 
subjects and 8 normotensive age-matched controls showed no significant 
associations, but there was one putative association between methylation of 
Sulfatase 1 (SULF1) gene and HTN(59). In another study of 60 hypertensive 
patients and controls, lower levels of 5mC were observed in DNA of patients with 
essential HTN (60). In animal models, a study of renal outer medullary tissue from 
the Dahl S hypertensive rat model and the SS.13BN26 congenic strain showed 
differential methylation in 80% of the CpG islands in response to salt (61).  
Whilst these studies offer exploratory support for the role of epigenetics in HTN, 
the evidence that epigenetic changes can explain the missing heritability is lacking 
(62-67) and further studies are clearly needed to assess the causal implications 
of epigenetics in BP regulation. 
Metabolomics 
Metabolomics is the systematic study of metabolites, which are small molecules 
generated by the process of metabolism, and has been important in elucidating the 
pathways underlying metabolic disorders. Metabolomic profiling of over 3000 adult 
twins identified a putative novel pathway for BP regulation involving a dicarboxylic acid 
(hexadecanedioate) with a causal role supported by in vivo studies in rats (68).  The 
role of hexadecanedioate in a vascular mechanism for HTN is supported by evidence 
from a study of pulmonary HTN, indicating a disruption of β-oxidation and an increase 
of ω-oxidation in this condition and pointing to a putative role in elevating pressure in 
both the systemic and the pulmonary circulations (69). The strongest genetic 
association seen with hexadecanedioate maps to Solute Carrier Organic Anion 
Transporter Family Member 1B1 (SLCO1B1), an association previously reported in a 
metabolome-wide genetic study in Caucasians (70). Targeted metabolomics profiling 
in the European Prospective Investigation Into Cancer and Nutrition (EPIC)-Potsdam 
study showed higher concentrations of serine, glycine, and acyl-alkyl-
phosphatidylcholines C42:4 and C44:3 tended to be associated with higher and diacyl-
phosphatidylcholines C38:4 and C38:3 with lower predicted 10-year HTN-free survival 
(71). Other metabolite associations with incident HTN and BP come from two US 
studies which found 4-hydroxyhippurate, a metabolic sex steroids pattern and 2 
diacylglycerols 16:0/22:5 and 16:0/22:6 to be associated with BP and incident HTN 
(72, 73). Finally, Menni et al. showed 12 metabolites to be strongly associated with 
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pulse wave velocity with uridine, phenylacetylglutamine, and serine appearing to 
strongly correlate with PWV in women (74).  
Some important factors to be addressed in future studies of BP as a quantitative trait 
would be to more accurately model BP in subjects on antihypertensive treatment by 
considering the number of drugs, drug dosage and adherence as well as the use of 
longitudinal BP data.  Novel strategies are needed to efficiently discover causal and 
clinically useful genetic markers. The next level of discovery will be more challenging 
as the molecular and functional dissection of the novel variants require more detailed 
functional studies in contrast to the high-throughput screening methods applied so 
far. The identification of a genomic approach to discover novel pathways and/or 
predict response (or lack of response) to existing anti-hypertensive drugs will be of 
benefit in developing the novel classes of drugs and may ultimately define an 
indication for them at an early stage in the treatment of HTN.  
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Table 1: Monogenic forms of hypertension 
Locus Position 
(GRCh38/ 
hg38) 
Gene/ 
Nearest 
genes 
Inheritance Genomic and Phenotypic annotation Therapeutic notes 
1p36.13 16043752 - 
16057308 
CLCNKB Autosomal 
Recessive 
 
Bartter syndrome, type 3, OMIM #607364. 
Low blood pressure. Impaired chloride 
reabsorption in the thick ascending loop of 
Henle leads to impaired sodium reabsorption. 
Hypokalemic metabolic alkalosis. Increased 
plasma renin and aldosterone. 
Sodium and potassium 
supplements 
Aldosterone inhibitors 
and angiotensin-
converting enzyme 
(ACE) inhibitors 
Indomethacin 
1p36.13 17018730 - 
17054170 
SDHB  Paragangliomas 4, OMIM #115310. 
Multiple catecholamine-secreting head and 
neck paragangliomas and 
pheochromocytomas. Adult onset. 
Alpha adrenergic 
blockers for 
pheochromocytoma 
1q23.3 161314376 
- 
161364745 
SDHC Autosomal 
Dominant 
Paragangliomas 3, OMIM #605373. 
Tumours or extra-adrenal paraganglia 
associated pheochromocytoma. 
Alpha adrenergic 
blockers for 
pheochromocytoma 
2q36.2 224470150 
- 
224585397 
CUL3 Autosomal 
Dominant 
Pseudohypoaldosteronism, type IIE, OMIM 
*603136. 
Thiazide diuretics 
21 
 
Hypertension, Hyperkalemia, Hyperchloremic 
metabolic acidosis 
3p25.3 10141635 - 
10153670 
VHL Autosomal 
Dominant 
von Hippel-Lindau syndrome, OMIM #193300 
Associated with retinal, cerebellar, and spinal 
hemangioblastoma, renal cell carcinoma 
(RCC), pheochromocytoma, and pancreatic 
tumours. 
Alpha adrenergic 
blockers for 
pheochromocytoma 
4q31.2 148078764 
- 
148442520 
NR3C2 Autosomal 
Dominant 
 
 
 
 
 
 
 
 
Autosomal 
Dominant 
Hypertension exacerbation in pregnancy, 
OMIM #605115. 
Missense mutation (S810L) in the 
mineralocorticoid receptor.  Low-renin, low-
aldosterone, hypokalemia. Progesterone and 
other steroids lacking 21-hydroxyl groups, 
normally MR antagonists, becoming potent 
agonists. 
 
Pseudohypoaldosteronism type I,OMIM 
#177735. 
Failure to thrive. Renal unresponsiveness to 
mineralocorticoids. Hyponatremia, 
Spironolactone 
contraindicated 
 
 
 
 
 
 
 
 
 
sodium chloride 
treatment 
22 
 
hyperkalemia, metabolic acidosis. Increased 
renin and aldosterone. 
5p15.3 218241 - 
256699 
SDHA  Paragangliomas 5, OMIM # 614165. 
Tumours or extra-adrenal paraganglia 
associated pheochromocytoma. 
Alpha adrenergic 
blockers for 
pheochromocytoma 
5q31.2 137617500 
- 
137736090 
KLHL3 Autosomal 
Dominant/ 
Recessive 
Pseudohypoaldosteronism, type IID, OMIM # 
614495. 
Hyperkalemia. Hyperchloremic metabolic 
acidosis 
Thiazide diuretics 
7p22.3-
7p22.1 
10001 - 
7239940 
 Autosomal 
Dominant 
Familial Hyperaldosteronism type 2, OMIM 
#605635.  
Hyperaldosteronism due to adrenocortical 
hyperplasia not suppressed by 
dexamethasone. 
 
7q36.1 150991056 
- 
151014599 
ABP1, 
KCNH2, 
NOS3, 
ACCN3, 
 NOS3 - Pregnancy induced Hypertension, 
OMIM +163729. 
Nitric Oxide plays an important role in the 
maintenance of cardiovascular and renal 
homeostasis 
 
23 
 
8q24.3 142872357 
- 
142917843 
CYP11B1, 
CYP11B2 
Autosomal 
Dominant 
 
 
 
 
Autosomal 
Recessive 
 
 
 
Autosomal 
Recessive 
 
Familial Hyperaldosteronism type 1 
Glucocorticoid Remediable Aldosteronism 
(GRA), OMIM #103900. 
Chimeric gene. Plasma and urinary 
aldosterone responsive to ACTH; 
dexamethasone suppressible within 48 h. 
Increased aldosterone and low renin. 
 
Corticosterone methyloxidase II deficiency, 
OMIM #61060. CYP11B2 
Enzymatic defect results in decreased 
aldosterone and salt-wasting, high plasma 
renin. 
 
Steroid 11β-hydroxylase deficiency, OMIM 
#202010. CYP11B1 
Neonatal onset. Virilisation, short stature, 
suppressed aldosterone and renin. 
Hypertension 
suppressed by 
dexamethasone 
 
 
 
 
Sodium chloride 
supplementation 
Fludrocortisone 
 
 
 
Glucocortioids  to reduce 
the ACTH-driven adrenal 
hyperplasia and 
production of the various 
hormone precursors. 
Potassium-sparing 
diuretics. 
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10q11.2 43077069 - 
43130349 
RET Autosomal 
Dominant 
Multiple Endocrine Neoplasia, Type IIA, 
OMIM #171400. 
Associated with multiple endocrine 
neoplasms, including medullary thyroid 
carcinoma, pheochromocytoma, and 
parathyroid adenomas. 
Alpha adrenergic 
blockers for 
pheochromocytoma 
10q24.3 102830531 
- 
102837533 
CYP17A1 Autosomal 
Recessive 
17-Alpha-Hydroxylase Deficiency, OMIM 
#202110. 
Hypertension, hypokalemic alkalosis. 
Increased ACTH and FSH.  Absent sexual 
maturation. 
Glucocortioids  to reduce 
the ACTH-driven adrenal 
hyperplasia and 
production of the various 
hormone precursors. 
Potassium-sparing 
diuretics. 
11q12.2 61430125 - 
61446767 
SDHAF2 Autosomal 
Dominant 
Paragangliomas 2, OMIM #601650. 
Tumours or extra-adrenal paraganglia 
associated pheochromocytoma. 
Alpha adrenergic 
blockers for 
pheochromocytoma 
11q23.1 112086847 
- 
112095794 
SDHD Autosomal 
Dominant 
Paragangliomas 1, OMIM #16800. 
Tumours or extra-adrenal paraganglia 
associated pheochromocytoma. 
Alpha adrenergic 
blockers for 
pheochromocytoma 
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11q24.3 128838020 
- 
128867373 
KCNJ1 Autosomal 
Recessive 
Bartter syndrome, antenatal, type 2, OMIM 
#241200. 
Reduced potassium recycling leads to 
impaired sodium reabsorption. Elevated 
plasma renin and aldosterone. Hypokalemia, 
hypochloremia, hyperprostaglandinuria 
Sodium and potassium 
supplements 
Aldosterone inhibitors 
and angiotensin-
converting enzyme 
(ACE) inhibitors 
Indomethacin 
12p12.3 -
12p11.1 
19847067 - 
33147066 
 Autosomal 
Dominant 
Hypertension with Brachydactyly Bilginturan 
syndrome, OMIM %112410. 
Brachydactyly, short phalanges, short 
metacarpals 
 
12p12.3 752923 - 
911452 
WNK1 Autosomal 
Dominant 
Pseudohypoaldosteronism type IIC Gordon's 
syndrome, OMIM #614492. 
Gain-of-function mutations in WNK1. 
Hyperchloremic metabolic acidosis. Low 
plasma renin, normal or elevated K+ 
Alkalizing agents, 
potassium-binding 
resins, prostaglandin 
inhibitors, and diuretics. 
15q21.1 48206301 - 
48304078 
SLC12A1 Autosomal 
Recessive 
Bartter syndrome, antenatal, type 1, OMIM 
#601678. 
Homozygous or compound heterozygous 
mutation in the sodium-potassium-chloride 
cotransporter-2 gene. 
Sodium and potassium 
supplements 
Aldosterone inhibitors 
and angiotensin-
26 
 
converting enzyme 
(ACE) inhibitors 
Indomethacin 
16p12.2 23302270 - 
23216879 
SCNN1B, 
SCNN1G 
Autosomal 
Dominant 
Liddle Syndrome, OMIM # 177200. 
Constitutive activation of epithelial sodium 
transporter, ENaC. Low plasma renin and 
aldosterone. Hypokalemia 
Amiloride or Triamterene 
16q13 56865207 - 
56915850 
SLC12A3 Autosomal 
Recessive 
Gitelman syndrome, OMIM #263800. 
Low BP. Loss-of-function mutation leads to 
lower sodium reabsorption. Increased plasma 
renin. Renal potassium and magnesium 
wasting.   
Potassium and 
magnesium 
supplements. NaCl 
intake. 
16q22.1 67431133 - 
67437551 
HSD11B2 Autosomal 
Recessive 
Apparent Mineralocorticoid Excess, OMIM # 
218030. 
Increased plasma ACTH. Increased urinary 
cortisol/cortisone ratio. Low plasma renin and 
aldosterone. 
Spironolactone 
17q21.2 42780631 - 
42797066 
WNK4 Autosomal 
Dominant  
Pseudohypoaldosteronism type IIB Gordon's 
syndrome, OMIM #614491. 
Loss-of-function mutations in WNK4. Low 
plasma renin, normal or elevated K+ 
Alkalizing agents, 
potassium-binding 
resins, prostaglandin 
inhibitors, and diuretics. 
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Table 2: GWAS results for BP and Hypertension in different ancestries 
Chr SNP Genotype 
Coded 
allele 
Coded allele frequency BP effect 
Nearest 
gene(s) 
    European Asian African European Asian African  
1p36.2 rs880315 C/T C 0.35 0.59 0.16 ↑ ↑ - CASZ1 
1p36.22 
rs17367504 A/G G 0.17 0.10 0.06 ↓ ↓ - MTHFR, 
CLCN6, 
NPPA, 
NPPB 
rs5068 C/T C 0.07 0.00 0.01 ↓ - - 
1p13.2 rs2932538 C/T C 0.73 0.80 0.85 ↓ - - SLC16A1, 
CAPZA1, 
ST7L, 
MOV10 
 rs17030613 A/C C 0.19 0.45 0.05 - ↑ - 
 rs10745332 A/G A 0.74 0.81 0.77 - ↑ - 
1q32.1 rs2169137 C/G G 0.74 0.94 0.80 ↑ - - MDM4 
1q42.2 rs2004776 A/G A 0.26 0.67 0.54 ↑ - - AGT 
2p23.2 rs1275988 A/G A 0.60 0.23 0.08 ↓ - - KCNK3 
2q11.2 rs7599598 A/G A 0.57 0.63 0.09 ↓ - - FER1L5 
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2q24.3 
rs1446468 A/G A 0.53 0.47 0.96 ↓ - - FIGN 
rs13002573 A/G G 0.25 0.40 0.11 ↓ - - FIGN 
rs16849225 C/T C 0.75 0.59 0.94 - ↑ - FIGN 
rs6749447 G/T G 0.28 0.72 0.58 ↑ - - STK39 
2q32.1 rs16823124 A/G A 0.23 0.51 0.10 ↑ - - PDE1A 
3p25.3 rs347591 G/T G 0.33 0.23 0.51 ↓ - - 
HRH1-
ATG7 
3p24.1 
rs13082711 C/T T 0.80 0.94 0.96 ↓ - - 
SLC4A 
rs820430 C/T T 0.64 0.40 1.00 ↑ - - 
3p22.1 rs9815354 A/G/T A 0.23 0.12 0.17 ↑ ↑ - 
ULK4  rs3774372 C/T T 0.77 0.87 0.81 ↓ - - 
 rs1717027 C/T T 0.22 0.12 0.66 ↑ - - 
3p21.31 rs319690 A/G A 0.51 0.75 0.41 ↑ - - 
MAP4 
 rs7651237 A/G G 0.64 0.94 0.88 ↑ - - 
30 
 
3p21.1 rs9810888 G/T G 0.53 0.59 0.46 - ↑ - CACNA1D 
3q26.1 rs16833934 A/G G 0.37 0.17 0.65 ↓ - - MIR1263 
3q26.2 rs419076 G/T T 0.48 0.13 0.57 ↑ - - MECOM 
4q12 rs871606 A/G A 0.87 0.78 0.76 ↑ ↑ - CHIC2 
4q21.21 
rs16998073 A/T T 0.19 0.30 0.05 ↑ ↑ - 
FGF5 
rs1458038 A/G A 0.27 0.34 0.05 ↑ - - 
4q24 rs13107325 A/C/T T 0.10 0.00 0.00 ↓ - - SLC39A8 
4q25 rs6825911 C/T C 0.20 0.48 0.54 - ↑ - 
ENPEP, 
PITX2 
4q32.1 rs13139571 A/C C 0.74 0.68 0.88 ↑ - - 
GUCY1A3-
GUCY1B3 
5p13.3 
rs1173771 C/T C 0.51 0.57 0.81 ↑ - - 
NPR3-
C5orf23 
rs7733331 C/T T 0.50 0.42 0.42 ↓ - - 
rs1173766 C/T C 0.52 0.59 0.62  ↑ - 
5q33.3 rs11953630 A/C/T T 0.34 0.06 0.15 ↓ - - EBF1 
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6p22.2 rs1799945 C/G G 0.18 0.04 0.00 ↑ ↑ - 
HFE 
 rs198823 G/T T 0.65 0.23 0.60 ↓ - - 
6p21.33 
rs805303 C/T C 0.70 0.57 0.30 ↑ - - BAG1 
rs2021783 C/T C 1.00 0.81 1.00 - ↑ - CYP21A2 
6p21.32 rs2854275 G/T T 0.08 0.03 0.08 ↓ - - HLA-DQB1 
6p21.1 rs10948071 C/T T 0.70 0.67 0.05 ↓ - - CRIP3 
6q22.33 rs13209747 C/G/T T 0.45 0.48 0.12 ↑ ↑ ↑ RSPO3 
6q25.1 rs17080102 C/G C 0.06 0.01 0.09 ↓ ↓ ↓ PLEKHG1 
7p15.2 rs17428471 G/T T 0.08 0.05 0.14 ↑ ↑ ↑ 
EVX1-
HOXA 
7p12.3 rs2949837 A/T A 0.23 0.61 0.00 ↑ - - IGFBP3 
7q21.2 rs2282978 C/T C 0.36 0.06 0.43 ↑ - - CDK6 
7q22.3 
rs17477177 C/T T 0.72 0.91 0.93 ↓ - - 
PIK3CG 
rs12705390 A/G G 0.72 0.91 0.93 ↓ - - 
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7q36.1 rs3918226 C/T T 0.10 0.00 0.00 ↑ - - NOS3 
8p23.1 rs4841569 A/G G 0.57 1.00 0.89 ↑ - - BLK-
GATA4  rs2898290 C/T C 0.58 0.02 0.55 NR - - 
8q24.12 rs2071518 C/T T 0.20 0.19 0.60 ↑ - - NOV 
10p12.31 
rs11014166 A/T A 0.63 0.97 0.89 ↑ ↓ - 
CACNB2 
rs1813353 A/G A 0.65 0.92 0.85 ↑ - - 
rs4373814 C/G G 0.63 0.53 0.43 ↓ - - 
rs12258967 C/G C 0.64 1.00 0.73 ↑ - - 
10q21.2 
rs1530440 C/T T 0.16 0.20 0.02 ↓ - - 
c10orf107 
rs4590817 C/G G 0.82 1.00 0.82 ↑ - - 
rs12244842 G/T T 0.25 0.19 0.35 ↓ - - 
rs7070797 A/G A 0.15 0.00 0.00 ↓ - - 
10q22.2 rs4746172 C/T C 0.23 0.56 0.19 ↑ - - VCL 
10q23.33 rs932764 A/G G 0.43 0.58 0.15 ↑ - - PLCE1 
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10q24.32 
rs1004467 C/T T 0.92 0.67 0.81 ↑ - - 
CYP17A1-
NT5C2 
rs11191548 C/T T 0.92 0.72 0.99 ↑ ↑ - 
rs12413409 A/G G 0.92 0.72 0.98 - ↑ - 
rs4409766 C/T T 0.93 0.78 0.82 - ↑ - 
rs3824755 C/G C 0.07 0.23 0.17 ↓ - - 
10q25.3 
rs2782980 C/T T 0.27 0.15 0.44 ↓ - - 
ADRB1 rs7076938 C/T C 0.33 0.17 0.45 ↓ - - 
rs1801253 C/G G 0.32 0.15 0.41 ↓ - - 
11p15.5 rs661348 C/T C 0.45 0.58 0.11 ↑ - - 
LSP1-
TNNT3 
11p15.4 rs7129220 A/G G 0.89 1.00 0.95 ↓ - - ADM 
11p15.1 
rs381815 A/C/T T 0.30 0.25 0.18 ↑ - - PLEKHA7 
rs757081 C/G G 0.63 0.66 1.00 ↑ - - 
PIK3C2A, 
NUCB2, 
NCR3LG1 
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11p15.2 
rs2014408 C/T T 0.20 0.21 0.03 ↑ ↑ ↑ 
SOX6 
rs4757391 C/T C 0.18 0.17 0.23 - ↑ - 
11q13.1 
rs4601790 A/G G 0.25 0.42 0.07 ↑ - - EHBP1L1 
rs3741378 A/G A 0.15 0.38 0.36 ↓ - - RELA 
11q22.1 rs633185 C/G G 0.68 0.55 0.82 ↓ - - 
FLJ32810-
TMEM133 
11q24.3 rs11222084 A/T T 0.40 0.07 0.26 ↑ - - ADAMTS8 
12q13.13 rs7297416 A/C C 0.25 0.62 0.38 ↓ - - HOXC4 
12q21.33 
rs11105354 A/G G 0.12 0.42 0.11 ↓ - - 
ATP2B1 
rs2681492 A/G A 0.88 0.58 0.84 ↑ - - 
rs2681472 C/T T 0.88 0.58 0.89 ↑ ↑ - 
rs17249754 A/G G 0.88 0.59 0.84 ↑ ↑ - 
12q24.12 
rs3184504 C/T T 0.45 0.00 0.00 ↑ - - 
SH2B3 
rs653178 A/G A 0.56 1.00 1.00 ↓ - - 
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12q24.13 rs11066280 A/T T 1.00 0.75 1.00 - ↑ - 
RPL6-
ALDH2 
12q24.21 
rs35444 C/T T 0.59 0.73 0.55 ↑ - - 
TBX5-
TBX3 
rs2384550 A/G A 0.37 0.09 0.34 ↓ - - 
rs10850411 C/T T 0.72 0.46 0.66 ↑ - - 
rs1991391 C/T C 0.64 0.91 0.58 ↑ - - 
rs11067763 A/G A 0.89 0.61 0.65 - ↑ - MED13L 
15q21.1 rs1036477 A/G G 0.10 0.42 0.61 ↓ - - FBN1 
15q24.1 
rs6495122 A/C A 0.38 0.78 0.78 ↑ - - CYP1A1-
ULK3 rs1378942 G/T G 0.32 0.79 1.00 ↑ - - 
15q24.2 
rs11072518 C/T T 0.34 0.42 0.44 ↑ - - 
COX5A 
rs1133323 A/G A 0.59 0.17 0.00 ↓ - - 
15q26.1 rs2521501 A/T T 0.63 0.93 0.80 ↑ - - 
FURIN-
FES 
16p12.3 rs13333226 A/G G 0.18 0.05 0.38 ↑ - - UMOD 
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16q22.1 rs33063 A/G A 0.19 0.15 0.00 ↑ - - NFAT5 
17q21.31 rs12946454 C/T T 0.71 0.62 0.80 ↑ - - PLCD3 
17q21.32 rs17608766 C/T T 0.91 1.00 1.00 ↓ - - GOSR2 
17q21.33 
rs12940887 C/T T 0.41 0.09 0.03 ↑ - - 
ZNF652 
rs16948048 A/G G 0.42 0.09 0.42 ↑ - - 
20p12.2 
rs1327235 A/G G 0.52 0.48 0.53 ↑ - - 
JAG1 
rs1887320 A/G A 0.58 0.43 0.54 - ↑ - 
20q13.32 
rs6015450 A/G G 0.07 0.00 0.22 ↑ - - 
GNAS-
EDN3 
rs6092743 A/G A 0.06 0.00 0.06 ↑ - - C20orf174 
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Figure 1: Genes and BP regulation. Genes linked to monogenic syndromes of high 
and low blood pressure are shown in bold black and genes that are putative loci from 
GWAS studies are in bold green. APA - aldosterone-producing adenoma; CAH – 
Congenital Adrenal Hyperplasia, HTB- Hypertension with Brachydactyly, GRA- 
Glucocorticoid Remediable Aldosteronism, PHA-I – PseudoHypoAldosteronism Type 
I, 
 
39 
 
 
Glossary of Terms 
Phenotype 
Phenotype or trait is the observable or measurable characteristic that is the target of 
genetic dissection.  
Genetic Architecture 
The genetic architecture of a trait refers to the number of distinct alleles that impact 
on the trait variation, their frequencies and penetrance. 
Penetrance 
Penetrance is the likelihood, or probability, that a particular genotype will be 
expressed in the phenotype. A penetrance of 100% means that the associated 
phenotype always occurs when the corresponding genotype is present, while a 
penetrance of 30% indicates that only 30% of those carrying a particular allele 
exhibit a phenotype. 
Heritability 
Heritability is the proportion of phenotypic variation due to the genetic differences 
between individuals within a population. Estimates of heritability can be used to 
describe the relative components of variance attributable to genetic factors and 
environmental factors. The heritability of a continuous trait is defined as the 
proportion of its total variance that is attributable to genetic factors in a particular 
population. 
Linkage disequilibrium (LD) 
LD can be simply defined as a non-random association between alleles at adjacent 
loci. That is, the presence of combination of alleles or markers in a population more 
often or less often than expected if the loci were segregating independently in the 
population. When a variant is first introduced into a population by mutation, it will be 
perfectly correlated with nearby variants, but over successive generations meiotic 
recombination will break up the correlations, and LD will decay. The LD between two 
markers within the same genomic region is commonly measured by the absolute 
value of D’ and r2. The higher the value of D’, the lower the possibility that a 
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recombination event occurred between these two loci (D’=1 means that the two 
markers have not been separated by a recombination event). The absolute value of 
r2 is more commonly used to quantify and compare LD in the context of mapping. 
When r2=1, the two markers have not been separated by recombination and have 
the same allele frequency. In this case of perfect LD, the two markers are completely 
linked and observation at one marker provides complete prediction about the other. 
Haplotype  
Haplotype is a linear arrangement of closely linked alleles on the same chromosome 
that is inherited as a unit. Individual’s genotypes at multiple tightly linked SNPs have 
two haplotypes, each containing alleles from one parent.    
The International HapMap project 
The international HapMap project (http://www.hapmap.org), has constructed 
genome-wide maps of LD patterns in multiple populations. One of the main 
objectives of the project is to identify set of SNPs that are in LD blocks to allow more 
efficient genotyping. 
Hardy Weinberg Equilibrium (HWE) 
The Hardy-Weinberg equilibrium states that allele and genotype frequencies in a 
population will remain constant from generation to generation in the absence of other 
evolutionary influences. 
Linkage studies  
The concept of linkage analysis is to search for alleles or chromosomal segments 
that are shared by affected relatives more than expected by random Mendelian 
segregation. These segments are passed entirely from the parents to the offspring 
without recombination at meiosis. Linkage analysis is only carried out in families with 
affected relatives, and involves genotyping of several markers that spread over the 
entire genome. Markers that flank the disease gene or mutation tend to highly 
segregate with disease status in families. Identifying markers within such a segment 
that consistently accompanies the disease may indicate presence of susceptibility 
genetic factors nearby these markers.  However, presences of such factors are 
neither necessary nor sufficient for the disease to develop.  
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Association Studies 
Association mapping is based on the idea that genetic variants underlying complex 
traits occur with a relatively high frequency (>1%), have undergone little or no 
selection in earlier populations and are likely to date back to >100,000 years ago 
(common disease common variant hypothesis). Association analysis has potentially 
far greater power than linkage analysis for detecting variants with modest effect on 
disease risk, provided that the genetic marker is close enough to exhibit strong 
linkage disequilibrium (LD) with the functional variant. Unless targeting a specific, 
known polymorphism, all genetic association studies utilize one important 
population-genomic feature in their design: linkage disequilibrium (LD). LD is an 
extremely useful feature, as it means investigators do not need to genotype all 
polymorphisms in a region of interest. Instead, they can select a subset of SNPs that 
are proxies for the majority of all common genetic variation nearby (so-called 
“tagSNPs”). 
Genome-wide Association studies (GWAS) 
Genome-wide association studies (GWAS) offer a hypothesis-free approach that 
systematically tests hundreds of thousands or more variants in the genome without 
prior knowledge of the location of the causal variants. GWA studies were made 
possible after assembling human genetic variants in large human genome reference 
projects such as the International HapMap Project, the Human Genome Project, and 
the 1000 Genome Project.  For GWAS studies, large sample sizes are required to 
generate sufficient statistical power to overcome the multiple hypotheses that are 
tested. The high number of false-positive results are addressed by stringent multiple 
testing correction and seeking evidence from multiple replication and validation 
studies of the top signals. GWAS are also blind to rare and structural variants. 
 
